Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India

References

• Dighiero G, Binet JL. Chronic lymphocytic leukemia. Hematol Cell Ther 1996;38:S41–S61.
   Google Scholar
• O’Brien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995;85: 307–318.
   PubMed Web of Science ®Google Scholar
• Dighiero G. Monoclonal B-cell lymphocytosis—a frequent premalignant condition. N Engl J Med 2008;359:638–640.
   PubMed Web of Science ®Google Scholar
• Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia—what do we need to know? Nat Rev Clin Oncol 2011;8: 38–47.
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Giannarelli D, . Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999;94:448–454.
   PubMed Web of Science ®Google Scholar
• Montserrat E, Gomis F, Vallespi T, . Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood 1991;78:1545–1551.
   PubMed Web of Science ®Google Scholar
• Molica S, Brugiatelli M, Callea V, . Comparison of younger versus older B cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. Eur J Haematol 1994;52:216–221.
   PubMed Web of Science ®Google Scholar
• Manoharan N, Tyagi BB, Raina V. Cancer incidences in rural Delhi– 2004 - 05.Asian Pac J Cancer Prev 2010;11:73–77.
   PubMed Web of Science ®Google Scholar
• Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst. 1999;10:861–868.
   Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, . Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219–234.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, . National Cancer Institute sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . International Workshop on Chronic Lymphocytic Leukemia Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;12:5446–5456.
   Web of Science ®Google Scholar
• Agrawal N, Naithani R, Mahapatra M, . Chronic lymphocytic leukemia in India—a clinico-hematological profile. Hematology 2007; 12:229–233.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wen S, O’Brien S, . Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2007; 25:4648–4656.
   PubMed Web of Science ®Google Scholar
• Karmiris T, Rohatiner AZ, Love S, . The management of chronic lymphocytic leukemia at a single centre over a 24-year period: prognostic factors for survival. Hematol Oncol 1994 1:29–39.
   Web of Science ®Google Scholar
• Molica S, Levato D. what is changing the natural history of chronic lymphocytic leukemia? Haematologica 2001;86:8–12.
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E. Current concepts: chronic lymphocytic leukemia. N Engl J Med 1995;333:1052–1057.
   PubMed Web of Science ®Google Scholar
• Rozman C, Bosch F, Monteserrat E. Chronic lymphocytic leukemia: a changing natural history? Leukemia 1997;11:775–778.
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, . Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230–239.
   PubMed Web of Science ®Google Scholar
• Wierda WG, O’Brien, Wang X. Prognostic normogram and index for overall survival in previously untreated patients of chronic lymphocytic leukemia. Blood 2007;107:4679–4685.
   Web of Science ®Google Scholar
• Del Poeta G, Maurillo L, Kimby E, . Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001;98: 2633–2639.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343: 1910–1916.
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–1757.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, . First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382–3391.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, . Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Adaoud A, . Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study. Blood 2007;110(Suppl. 1): Abstract 2043.
   Google Scholar
• Flinn IW, Neuberg DS, Grever MR, . Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol 2007;25:793–798.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, . Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107: 885–891.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, .; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010 2;376:1164–1174.
   Web of Science ®Google Scholar